Phase II study of panitumumab combined with capecitabine and oxaliplatin as first-line treatment in metastatic colorectal cancer patients: clinical results including extended tumor genotyping
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Phase II study of panitumumab combined with capecitabine and oxaliplatin as first-line treatment in metastatic colorectal cancer patients: clinical results including extended tumor genotyping
Authors
Keywords
Metastatic colorectal cancer, Panitumumab, Tumor sidedness, <em class=EmphasisTypeItalic >TP53</em>, Next generation sequencing
Journal
MEDICAL ONCOLOGY
Volume 35, Issue 7, Pages -
Publisher
Springer Nature
Online
2018-05-31
DOI
10.1007/s12032-018-1160-1
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Sidedness and TP53 mutations impact OS in anti-EGFR but not anti-VEGF treated mCRC - an analysis of the KRAS registry of the AGMT (Arbeitsgemeinschaft Medikamentöse Tumortherapie)
- (2018) Florian Huemer et al. BMC CANCER
- The relevance of primary tumour location in patients with metastatic colorectal cancer: A meta-analysis of first-line clinical trials
- (2017) Julian Walter Holch et al. EUROPEAN JOURNAL OF CANCER
- Right Versus Left Colon Cancer Biology: Integrating the Consensus Molecular Subtypes
- (2017) Michael S. Lee et al. Journal of the National Comprehensive Cancer Network
- Assessment of Pharmacokinetic Interaction Between Capecitabine and Cetuximab in Metastatic Colorectal Cancer Patients
- (2016) VERONIKA RACHAR et al. ANTICANCER RESEARCH
- A Phase II Study of XELOX and Cetuximab as First-Line Therapy in Patients With KRAS Wild Type Metastatic Colorectal Cancer (FLEET2 Study)
- (2016) Shoichi Hazama et al. Clinical Colorectal Cancer
- Rational bases for the use of the Immunoscore in routine clinical settings as a prognostic and predictive biomarker in cancer patients
- (2016) Amos Kirilovsky et al. INTERNATIONAL IMMUNOLOGY
- Is sidedness prognostically important across all stages of colorectal cancer?
- (2016) David J Kerr et al. LANCET ONCOLOGY
- A multigene mutation classification of 468 colorectal cancers reveals a prognostic role for APC
- (2016) Michael J. Schell et al. Nature Communications
- Role of targeted therapy in metastatic colorectal cancer
- (2016) Yoshihito Ohhara et al. World Journal of Gastrointestinal Oncology
- Heterogeneity of KRAS, NRAS, BRAF and PIK3CA mutations in metastatic colorectal cancer and potential effects on therapy in the CAPRI GOIM trial
- (2015) N. Normanno et al. ANNALS OF ONCOLOGY
- Fluorouracil, Leucovorin, and Irinotecan Plus Cetuximab Treatment andRASMutations in Colorectal Cancer
- (2015) Eric Van Cutsem et al. JOURNAL OF CLINICAL ONCOLOGY
- Primary Tumor Location as a Prognostic Factor in Metastatic Colorectal Cancer
- (2015) Fotios Loupakis et al. JNCI-Journal of the National Cancer Institute
- Clonal status of actionable driver events and the timing of mutational processes in cancer evolution
- (2015) Nicholas McGranahan et al. Science Translational Medicine
- p53mutations in colorectal cancer- molecular pathogenesis and pharmacological reactivation
- (2015) Xiao-Lan Li WORLD JOURNAL OF GASTROENTEROLOGY
- Primary Tumor Location as a Prognostic Factor in Metastatic Colorectal Cancer
- (2015) Fotios Loupakis et al. JNCI-Journal of the National Cancer Institute
- Clinical activity of FOLFIRI plus cetuximab according to extended gene mutation status by next-generation sequencing: findings from the CAPRI-GOIM trial
- (2014) F. Ciardiello et al. ANNALS OF ONCOLOGY
- Mutational analysis and clinical correlation of metastatic colorectal cancer
- (2014) Andrea L. Russo et al. CANCER
- PEAK: A Randomized, Multicenter Phase II Study of Panitumumab Plus Modified Fluorouracil, Leucovorin, and Oxaliplatin (mFOLFOX6) or Bevacizumab Plus mFOLFOX6 in Patients With Previously Untreated, Unresectable, Wild-Type KRAS Exon 2 Metastatic Colorectal Cancer
- (2014) Lee S. Schwartzberg et al. JOURNAL OF CLINICAL ONCOLOGY
- FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial
- (2014) Volker Heinemann et al. LANCET ONCOLOGY
- HER2 gene copy number status may influence clinical efficacy to anti-EGFR monoclonal antibodies in metastatic colorectal cancer patients
- (2013) V Martin et al. BRITISH JOURNAL OF CANCER
- Colorectal cancer
- (2013) Hermann Brenner et al. LANCET
- The predictive role of skin rash with cetuximab and panitumumab in colorectal cancer patients: a systematic review and meta-analysis of published trials
- (2013) F. Petrelli et al. Targeted Oncology
- Tumour angiogenesis regulation by the miR-200 family
- (2013) Chad V. Pecot et al. Nature Communications
- Prognostic Significance of Tumor-Infiltrating Lymphocytes for Patients With Colorectal Cancer
- (2012) Jae Hyuk Lee ARCHIVES OF SURGERY
- Comparative Genomic Analysis of Primary Versus Metastatic Colorectal Carcinomas
- (2012) Efsevia Vakiani et al. JOURNAL OF CLINICAL ONCOLOGY
- Identification of a mutation in the extracellular domain of the Epidermal Growth Factor Receptor conferring cetuximab resistance in colorectal cancer
- (2012) Clara Montagut et al. NATURE MEDICINE
- Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study
- (2011) C. Bokemeyer et al. ANNALS OF ONCOLOGY
- Section E9 of the American College of Medical Genetics technical standards and guidelines: Fluorescence in situ hybridization
- (2011) James T Mascarello et al. GENETICS IN MEDICINE
- Cetuximab Plus Capecitabine and Irinotecan Compared With Cetuximab Plus Capecitabine and Oxaliplatin As First-Line Treatment for Patients With Metastatic Colorectal Cancer: AIO KRK-0104—A Randomized Trial of the German AIO CRC Study Group
- (2011) Nicolas Moosmann et al. JOURNAL OF CLINICAL ONCOLOGY
- Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial
- (2011) Timothy S Maughan et al. LANCET
- Randomized, Phase III Trial of Panitumumab With Infusional Fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX4) Versus FOLFOX4 Alone As First-Line Treatment in Patients With Previously Untreated Metastatic Colorectal Cancer: The PRIME Study
- (2010) Jean-Yves Douillard et al. JOURNAL OF CLINICAL ONCOLOGY
- Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis
- (2010) Wendy De Roock et al. LANCET ONCOLOGY
- TP53 mutations predict disease control in metastatic colorectal cancer treated with cetuximab-based chemotherapy
- (2009) A Oden-Gangloff et al. BRITISH JOURNAL OF CANCER
- Targeted KRAS Mutation Assessment on Patient Tumor Histologic Material in Real Time Diagnostics
- (2009) Vassiliki Kotoula et al. PLoS One
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now